Advanced

A population-based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden.

Epstein, Elisabeth LU ; Lindqvist, Pelle LU and Olsson, Håkan LU (2009) In International Journal of Cancer 125. p.421-425
Abstract
Our aim was to determine the risk of endometrial cancer associated with long-term use of combined hormone therapy (HT) and low-potency estrogens. In this prospective population-based cohort, 40,000 women aged 25-64 years, without prior cancer or hysterectomy, were included. The women answered 2 questionnaires at a 10-year interval regarding HT use and personal details. Women were followed up for an average of 15.5 years through the National Cancer and Causes of Death Registry, representing 236,611 women years. Among the 17,822 postmenopausal women included, 166 cases of endometrial cancer were diagnosed. Only use of combined HT was related to a decreased risk of endometrial cancer (OR 0.3, 95% CI 0.1-0.8), the protective effect was found... (More)
Our aim was to determine the risk of endometrial cancer associated with long-term use of combined hormone therapy (HT) and low-potency estrogens. In this prospective population-based cohort, 40,000 women aged 25-64 years, without prior cancer or hysterectomy, were included. The women answered 2 questionnaires at a 10-year interval regarding HT use and personal details. Women were followed up for an average of 15.5 years through the National Cancer and Causes of Death Registry, representing 236,611 women years. Among the 17,822 postmenopausal women included, 166 cases of endometrial cancer were diagnosed. Only use of combined HT was related to a decreased risk of endometrial cancer (OR 0.3, 95% CI 0.1-0.8), the protective effect was found after 2 years, and increased with extended duration of use. "Only use" of low-potency estrogens increased the risk of endometrial cancer almost to the same extent as use of high-potency estrogens (OR 2.0, 95% CI 1.1-3.6 vs. OR 2.5, 95% CI 1.3-4.8), the increased risk was confined to non-obese women in both groups. The risk was significantly increased for oral but not for local low-potency estrogen users (OR 2.1, 95% CI 1.1-3.6 vs. OR 1.5, 95% CI 0.4-6.2, respectively). In long-term estrogen users the risk was highest during the first 2 years, dropping slightly thereafter. Since low-potency estrogen use increases the risk of endometrial cancer almost as much as high-potency estrogen use, they should only be given if medically indicated. (c) 2009 UICC. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International Journal of Cancer
volume
125
pages
421 - 425
publisher
John Wiley & Sons
external identifiers
  • wos:000267231600022
  • pmid:19326453
  • scopus:67449095070
ISSN
0020-7136
DOI
10.1002/ijc.24284
language
English
LU publication?
yes
id
d2daef20-4a0a-4921-bcf0-7d6b4c6a228f (old id 1367417)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19326453?dopt=Abstract
date added to LUP
2009-04-06 16:03:33
date last changed
2017-01-01 07:39:56
@article{d2daef20-4a0a-4921-bcf0-7d6b4c6a228f,
  abstract     = {Our aim was to determine the risk of endometrial cancer associated with long-term use of combined hormone therapy (HT) and low-potency estrogens. In this prospective population-based cohort, 40,000 women aged 25-64 years, without prior cancer or hysterectomy, were included. The women answered 2 questionnaires at a 10-year interval regarding HT use and personal details. Women were followed up for an average of 15.5 years through the National Cancer and Causes of Death Registry, representing 236,611 women years. Among the 17,822 postmenopausal women included, 166 cases of endometrial cancer were diagnosed. Only use of combined HT was related to a decreased risk of endometrial cancer (OR 0.3, 95% CI 0.1-0.8), the protective effect was found after 2 years, and increased with extended duration of use. "Only use" of low-potency estrogens increased the risk of endometrial cancer almost to the same extent as use of high-potency estrogens (OR 2.0, 95% CI 1.1-3.6 vs. OR 2.5, 95% CI 1.3-4.8), the increased risk was confined to non-obese women in both groups. The risk was significantly increased for oral but not for local low-potency estrogen users (OR 2.1, 95% CI 1.1-3.6 vs. OR 1.5, 95% CI 0.4-6.2, respectively). In long-term estrogen users the risk was highest during the first 2 years, dropping slightly thereafter. Since low-potency estrogen use increases the risk of endometrial cancer almost as much as high-potency estrogen use, they should only be given if medically indicated. (c) 2009 UICC.},
  author       = {Epstein, Elisabeth and Lindqvist, Pelle and Olsson, Håkan},
  issn         = {0020-7136},
  language     = {eng},
  pages        = {421--425},
  publisher    = {John Wiley & Sons},
  series       = {International Journal of Cancer},
  title        = {A population-based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden.},
  url          = {http://dx.doi.org/10.1002/ijc.24284},
  volume       = {125},
  year         = {2009},
}